MedTrace Logo

Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate Cancer

NCT00138918 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-03-03

No results posted yet for this study

Summary

The purpose of this trial is to assess the effects of combined therapy with androgen ablation and OGX-011 (an antisense to clusterin) given prior to radical prostatectomy on pathologic complete response rates in men with localized prostate cancer and high risk features.

Conditions

Interventions

BIOLOGICAL

OGX-011

See Detailed Description, Treatment Plan

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Dr. Kim Chi · University of British Columbia

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2008-05-13
Completion
2008-05-13

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00138918 on ClinicalTrials.gov